Patents by Inventor Andrew E. Gelman
Andrew E. Gelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11351227Abstract: The present disclosure generally provides compositions and methods related to the field of immunology. Specifically, disclosed herein are chemokine binding proteins and methods of use thereof.Type: GrantFiled: April 27, 2018Date of Patent: June 7, 2022Assignee: Washington UniversityInventors: Daved Fremont, Olga Lubman, Andrew E. Gelman, Yun Hsuan Lu
-
Publication number: 20200164032Abstract: The present disclosure generally provides compositions and methods related to the field of immunology. Specifically, disclosed herein are chemokine binding proteins and methods of use thereof.Type: ApplicationFiled: April 27, 2018Publication date: May 28, 2020Inventors: Daved Fremont, Olga Lubman, Andrew E. Gelman, Yun Hsuan Lu
-
Patent number: 9822362Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene.Type: GrantFiled: October 28, 2015Date of Patent: November 21, 2017Assignees: Quark Pharmaceuticals Inc., Washington UniversityInventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
-
Publication number: 20160215284Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising down-regulating the TLR2 gene or both the TLR2 gene and TLR4 gene.Type: ApplicationFiled: October 28, 2015Publication date: July 28, 2016Inventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
-
Patent number: 9205100Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene.Type: GrantFiled: March 1, 2012Date of Patent: December 8, 2015Assignees: Quark Pharmaceuticals, Inc., Washington UniversityInventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
-
Publication number: 20140005253Abstract: Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene.Type: ApplicationFiled: March 1, 2012Publication date: January 2, 2014Applicants: WASHINGTON UNIVERSITY, QUARK PHARMACEUTICALS, INC.Inventors: Andrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
-
Publication number: 20090220528Abstract: The present invention relates to compositions and methods for modulating Toll-like receptors (TLRs) for enhancing survival of activated CD4+ T cells. The enhanced survival of activated CD4+ T cells provides a means for regulating an immune response.Type: ApplicationFiled: June 15, 2006Publication date: September 3, 2009Applicant: THE TRUSTEES OF THE UNIVERISTY OF PENNSYLVANIA CNETER FOR TECHNOLOGY TRANSFERInventors: Laurence Turka, Andrew E. Gelman
-
Patent number: 5639505Abstract: Articles of manufacture which are adapted for use in contact with one or more biologically active agents are coated with a glassy carbohydrate film. The glassy film provides a reduced surface energy coating which exhibits a reduced degree of binding with biologically active agents. Methods for applying the glassy carbohydrate film are disclosed wherein the glassy film is adsorbed directly onto the article surface.The coated articles are for use both in vitro and in vivo where contact with biologically active agents is expected.Type: GrantFiled: May 23, 1995Date of Patent: June 17, 1997Assignee: The Regents of the University of CaliforniaInventors: Nir Kossovsky, Andrew E. Gelman, Edward E. Sponsler
-
Patent number: 5464634Abstract: A red blood cell surrogate which is composed of a nanocrystalline core particle to which an oxygen carrier such as hemoglobin is bound. An oxygen carrier anchor coating is provided between the nanocrystalline core particle and the oxygen carrier in order to provide binding of the oxygen carrier to the nanocrystalline core particle without denaturing the oxygen carrier or otherwise destroying its oxygen carrying capacity. The nanocrystalline core particle with the oxygen carrier bound thereto is coated with a layer of lipid and then an outer layer of a sugar or allosteric effector is applied.Type: GrantFiled: April 25, 1994Date of Patent: November 7, 1995Assignee: The Regents of the University of CaliforniaInventors: Nir Kossovsky, Andrew E. Gelman, H. James Hnatyszyn
-
Patent number: 5441739Abstract: Articles of manufacture which are adapted for use in contact with one or more biologically active agents are coated with a glassy carbohydrate film. The glassy film provides a reduced surface energy coating which exhibits a reduced degree of binding with biologically active agents. Methods for applying the glassy carbohydrate film are disclosed wherein the glassy film is adsorbed directly onto the article surface. The coated articles are for use both in vitro and in vivo where contact with biologically active agents is expected.Type: GrantFiled: March 11, 1993Date of Patent: August 15, 1995Assignee: The Regents of the University of CaliforniaInventors: Nir Kossovsky, Andrew E. Gelman, Edward E. Sponsler
-
Patent number: 5334394Abstract: A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When Human Immunodeficiency Virus (HIV) viral protein is attached to the core particles, the result is a viral decoy which accurately mimics native HIV in size, structure and surface character while being entirely devoid of virulent activity due to the microparticle core. The HIV decoy is useful as a vaccine for treating mammals to elicit an immune response.Type: GrantFiled: January 4, 1993Date of Patent: August 2, 1994Assignee: The Regents of the University of CaliforniaInventors: Nir Kossovsky, Andrew E. Gelman, Edward E. Sponsler
-
Patent number: 5306508Abstract: A red blood cell surrogate which is composed of a nanocrystalline core particle to which an oxygen carrier such as hemoglobin is bound. An oxygen carrier anchor coating is provided between the nanocrystalline core particle and the oxygen carrier in order to provide binding of the oxygen carrier to the nanocrystalline core particle without denaturing the oxygen carrier or otherwise destroying its oxygen carrying capacity. The nanocrystalline core particle with the oxygen carrier bound thereto is coated with an exterior layer of lipid.Type: GrantFiled: March 11, 1993Date of Patent: April 26, 1994Assignee: The Regents of the University of CaliforniaInventors: Nir Kossovsky, Andrew E. Gelman, Edward E. Sponsler